Get the Stockscreener App
143.97
5.38%
7.35
After Hours:
144.65
0.68
+0.47%
Moderna Inc stock is traded at $143.97, with a volume of 15.41M.
It is up +5.38% in the last 24 hours and up +137.69% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$136.62
Open:
$137.905
24h Volume:
15.41M
Relative Volume:
1.01
Market Cap:
$57.48B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-17.67
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-1.09%
1M Performance:
+137.69%
6M Performance:
+157.23%
1Y Performance:
+467.03%
1-Day Range:
$135.01
$149.73
1-Week Range:
$130.38
$149.73
52-Week Range:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
143.97 | 54.54B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 81.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.56B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.59B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna stock gains after a 6.7 percent jump - ad-hoc-news.de
Healthcare Stocks To Keep An Eye OnSeptember 11th - MarketBeat
Moderna Inc Stock (MRNA) Moved Up by 8.63% on Sep 11: A Full Analysis - TradingKey
MRNA Looks 517.6% Overvalued on GF Value™ as Price-to-Sales Soars Amid Losses - GuruFocus
MRNA Stock Climbs As Analysts Back Oncology And Vaccine Push - StocksToTrade
MRNA Stock Climbs As Oncology Catalysts And Upgrades Pile Up - timothysykes.com
Moderna (NASDAQ:MRNA) Shares Up 6.7%Should You Buy? - MarketBeat
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - The Globe and Mail
Best Biotech Stocks To Watch NowSeptember 11th - MarketBeat
Moderna climbs 8% as volatile trading continues (MRNA:NASDAQ) - Seeking Alpha
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat - Yahoo Finance
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Zacks Investment Research
Why is Moderna stock rallying today? By Investing.com - Investing.com Canada
Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On Friday - Benzinga
Why Is the Market Watching Moderna (MRNA)? - Kalkine Media
Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Rep. Maria Elvira Salazar Sells Moderna, Inc. (NASDAQ:MRNA) Stock - MarketBeat
Rep. Maria Elvira Salazar Acquires Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions - TradingView
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna (NASDAQ: MRNA) officer plans multimillion-dollar stock sale - Stock Titan
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance Singapore
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $4.44 Million in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc aStock (AMRNA) Price Prediction for 2026 to 2031 - Bybit
Moderna Inc. stock surges after cancer vaccine data as one-month gain tops 130 percent - ad-hoc-news.de
Biotech Stocks To ConsiderSeptember 9th - MarketBeat
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says - marketscreener.com
Moderna, Inc. • Robinhood Token (MRNA) Price Prediction for 2026 to 2031 - Bybit
Moderna stock heads into the open after a 1.8 percent drop - AD HOC NEWS
Discipline and Rules-Based Execution in MRNA Response - Stock Traders Daily
Moderna (NASDAQ: MRNA) withholds 5,704 shares for legal chief’s RSU taxes - Stock Titan
Moderna (NASDAQ: MRNA) CFO now holds 106,179 unvested RSUs - Stock Titan
What to know about a first-of-its kind flu shot for people over 50 - nbcchicago.com
Merck and Moderna Announce Positive Phase 3 Results for Intismeran Autogene Plus Pembrolizumab in High-Risk MelanomaThe Babak Lab - oncodaily.com
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? - The Globe and Mail
Moderna Inc. stock gains sharply as cancer vaccine data lifts valuation - AD HOC NEWS
Nykredit A S Invests $913,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Moderna Inc. stock gains strongly as cancer vaccine partnership fuels rally - AD HOC NEWS
Moderna Stock (MRNA) Opinions on Melanoma Vaccine Trial Results - Quiver Quantitative
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks - Yahoo Finance
Moderna, Inc. (MRNA) Stock Analysis: Is the Biotech Giant’s Market Cap Justified Amid a 19.96% Potential Downside? - DirectorsTalk Interviews
Alibaba DAMO Academy's Liver Cancer AI Model Tops Nature Medicine; Clinical Trial Catches 15 Missed Diagnoses - finance.biggo.com
Moderna Expands mRNA Territory Beyond Personalized Cancer Vaccines to Universal Shots and In Vivo CAR-T - finance.biggo.com
Moderna Moves Beyond Personalized Cancer Vaccines to Universal Shot - Seoul Economic Daily
Moderna Inc. stock holds steady as investors watch vaccine revenue and oncology pipeline - AD HOC NEWS
MRNA Looks 503.7% Overvalued on GF Value™ - GuruFocus
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - MarketBeat
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.) - Yahoo Finance
AlphaGrep UK Ltd Invests $568,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):